{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Administer study drug and record date, volume and rate of infusion, and start/stop times', 'of dosing.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic at Week 24.', '9.5.6.11 Week 24/Premature Withdrawal - Treatment Period', 'Week 24 is the final visit of the Treatment Period. Study drug is not administered.', 'Obtain blood samples for hematology and chemistry (including thyroid, glucose, and', 'HbA1c) analysis (see Section 9.5.4.6 for details concerning test results and study', 'participation).', 'Collect urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential.', 'Collect blood sample for immunogenicity testing (only subjects who complete the', 'Treatment Period, not those who prematurely discontinue study drug administration).', 'Collect blood sample for PK analyses (only subjects who complete the Treatment Period,', 'not those who prematurely discontinue study drug administration).', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Perform 12-lead ECG.', 'Perform physical and ophthalmic examinations, including vital signs.', 'Measure weight.', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Administer GO-QoL questionnaire.', 'Subjects who were proptosis non-responders in Study HZNP-TEP-301 will enter the Follow-Up', 'Period and will be instructed to return to the clinic in one month for the first follow-up visit.', 'Subjects who relapsed during the Follow-Up Period of HZNP-TEP-301 and chose to enter this', 'extension study will not participate in the Follow-Up Period.', '9.5.6.12 Month 7 - Follow-Up Period', 'Collect urine sample for a pregnancy test for females of childbearing potential.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 101 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Collect vital signs.', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Administer GO-QoL questionnaire.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic for the Month 9 Follow-Up Visit.', '9.5.6.13 Month 9 - Follow-Up Period', 'Obtain blood samples for hematology and chemistry (including thyroid, glucose, and', 'HbA1c) analysis.', 'Collect urine sample for urinalysis and also for a pregnancy test for females of', 'childbearing potential.', 'Enquire about signs and symptoms and concomitant medications throughout the visit.', 'Collect blood sample for immunogenicity testing.', 'Collect vital signs.', 'Perform efficacy assessments (CAS, Clinical Measures of Severity including proptosis,', 'diplopia and motility restriction).', 'Measure weight.', 'Subjects will be discharged from the study center after all of the procedures have been completed', 'and will be instructed to return to the clinic at Month 12.', '9.5.6.14 Month 12', '9.5.6.14.1 Month 12/Premature Withdrawal - Follow-Up Period for Proptosis', 'Non-responders in Study HZNP-TEP-301', 'Obtain blood samples for hematology and chemistry (including thyroid, glucose, and', 'HbA1c) analysis.', 'Collect urine sample for urinalysis.', 'Collect urine sample for a pregnancy test for females of childbearing potential if the', 'subject discontinued from the study prior to Month 9 of the Follow-Up Period.', 'Collect blood sample for immunogenicity testing.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 102 of 118']\n\n###\n\n", "completion": "END"}